NeuroSense (NRSN) stock soars 35% after Alzheimer's study results

June 30, 2022 10:21 PM IST | By Versha Jain
 NeuroSense (NRSN) stock soars 35% after Alzheimer's study results
Image source: © Skypixel | Megapixl.com

Highlights:

  • Israel-based NeuroSense Therapeutics develops drugs for neurodegenerative diseases.
  • The company was founded in 2017 and listed on Nasdaq in December 2021.
  • Its current market capitalization is US$42.3 million. 

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) stock soared on Thursday after announcing the results of its biomarker study for treating Alzheimer's disease.

The stock traded at US$3.7106, up 35.42%, at 10:43 am ET. The company carried out a biomarker study to evaluate the potential of its drug CogniC for treating Alzheimer's. 

The study could identify biomarkers suggesting that CogniC might be effective against the disease. It targets pathways, such as miRNA dysregulation, impaired autophagy, and lysosomal dysfunction, leading to Alzheimer's. 

The study also detected Alzheimer's traits, including increased levels of amyloid-β and intracellular tau protein aggregates.

NeuroSense CEO Alon Ben-Noon said the company plans to conduct a clinical proof-of-concept study after identifying the biomarkers. He added that the study could start in 2023. 

The study used the Neuron-Derived Exosomes (NDE) technology that helps observe biomarkers alterations in the central nervous system through blood samples in a non-invasive manner.  

Israel-based NeuroSense, which develops treatments for neurodegenerative diseases, was founded in 2017 before its listing on Nasdaq in December 2021.

After further analysis, the company plans to share the detailed results on novel biomarkers in scientific conferences and peer-reviewed publications.

Financials:

Its current market capitalization is US$42.3 million. 

The stock touched the highest price of US$8.18 and the lowest of US$1.23 in the last 52 weeks. 

The company reported zero revenue for the quarter ended March 31, 2022. Its net loss was US$2.71 million or US$0.24 per diluted share compared to a net loss of US$2.12 million or US$0.38 per share diluted in the same quarter prior year, reflecting an increase of US$0.59 million. The increase was due to higher general and administrative expenses. 

Its cash and short-term deposits were US$13.74 million as of March 31, 2022, compared to US$11.06 million as of December 31, 2021.

Bottom line:

Alzheimer's is a brain disorder where patients suffer memory loss and gradual cognitive decline. It could lead to a more serious brain disease called dementia. The company said in a statement that 60-80% of dementia cases first suffer from Alzheimer's. It expects the market for Alzheimer's treatment to grow to US$5 billion in 2022.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.